These results suggest that CIN is adversely associated with the outcome of EGFR-TKI treatment in patients with EGFR-mutated NSCLC, which could be independent of other factors influencing the treatment response, including TP53 and EGFR mutations. The gene discussed is TP53; the disease is non-small cell lung carcinoma.